Global Liquid Biopsy Market Research Report- Forecast to 2022

Global Liquid Biopsy Market Research Report- Forecast to 2022

ID: MRFR/HC/0239-CRR | April, 2017 | Region: Global | 171 pages | Cooked Research Reports

Global Liquid Biopsy Market Information, by Biomarker Types (Circulating Tumor Cells (Ctcs), Circulating Tumor Dna (Ctdna), Extracellular Vesicles (Evs) and Other Biomarker (Circulating Rna And Proteins), by Application (Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application), by Sample (Blood Sample, Urine Sample, Other) And End User (Hospitals and Laboratories, Academic And Research Centers, Other End Users) - Forecast to 2022



Market Synopsis of Global Liquid Biopsy market:


Market Scenario:


A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science namely human genome sequencing and rising sensitivity of detecting techniques and assays.


The global Liquid Biopsy market is currently valued at $ 3950 million and will reach $ 17,372.28 million growing at a CAGR of 28%. The growth factors responsible for this explosive growth are liquid biopsy is a comparatively painless and non-invasive technique which provides early real time high precision detection of diseases which could be used for monitoring and designing effective treatment strategies based on the real time molecular assessment for the progression of the disease. Other factors driving the liquid biopsy market are lifestyle changes and environmental factors such as rising investment in research and development and collaborations between companies and public organizations, rise in population particularly geriatric population, rising expenditure on health etc. The technique also has other advantages over traditional tissue biopsy such as potential applications to cardiovascular diseases, autoimmune diseases etc.


The restraints include the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. Also not all cancer patients benefit from early detection as some cancers such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.


Global Liquid Biopsy Market, by Region 2015 (% share) 


 Liquid Biopsy Market Image


Intended Audience



  • Global Liquid Biopsy test kit manufacturers

  • Global Liquid Biopsy test kit suppliers

  • Research and development Laboratories

  • Market Research and Consulting Service Providers


Key findings



  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.

  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.

  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period



Key Players for Global Liquid Biopsy market:


Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics,  Inivata Ltd.,  SAGA Diagnostics AB,  Exosome Diagnostics and others.



Segments:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centers and others.


Regional Analysis of Global Liquid Biopsy market:


Globally North America is the largest market for Global Liquid Biopsy market. Europe is the second-largest market for Global Liquid Biopsy market. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future. North America accounted for the largest market share of 37.95% in 2016 accounting for a market value of 1,499.10 million in  2016. Asia pacific is the fastest growing market which is growing at a CAGR of 28.8%.



The report for
Global Liquid Biopsy market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
TABLE OF CONTENTS

2.1 Scope of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

2.4 Market Structure

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4.1 Introduction

4.2 Drivers

4.2.1 Comparatively painless and non-invasive technique

4.2.2 Early real time high precision detection of diseases

4.2.3 Useful for designing effective treatment strategies based on the real time molecular assessment for the progression of the disease

4.2.4 Rise in cases of cancer and other diseases

4.2.5 Lifestyle changes and environmental factors

4.2.6 Other advantages over other techniques

4.2.7 The recent technological advancements has increased the appeal of liquid biopsy

4.2.8 Transferability of liquid biopsy

4.2.9 Rising investment in research and development and collaborations between companies and public organizations

4.2.10 Greater focus on venture capital

4.2.11 Demographical factors

4.3 Restraints

4.3.1 Prohibitive costs associated with liquid biopsy

4.3.2 Lower sensitivity for certain biomarkers

4.3.3 Not all cancers patients benefit from early detection

4.3.4 Liquid biopsy is not all non-invasive

4.3.5 Differential awareness and availability between developing and developed world

4.3.6 Issues in venture capital, startups and collaborations

4.4 Opportunities

4.4.1 Growing collaboration between companies has become the entrance gateway for new firms

4.4.2 Funding from public organizations is a good strategy to reduce development costs

4.4.3 Rise in research and development investment

4.4.4 Developing economies provide an unserved market for liquid biopsy

4.4.5 Growing trend of start-ups and venture investment in the field of liquid biopsy

4.5 Challenges

4.5.1 Information and interest gap between the investors and the developers

4.5.2 Lack of trained professionals in developing regions

4.5.3 Lack of standardization and transparency

5.1 Porter’s Five Force Analysis

5.1.1 Bargaining Power of Buyer

5.1.2 Bargaining Power of Supplier

5.1.3 Threat from substitute

5.1.4 Threat from a New Entrant

5.1.5 Intensity of Competitive Rivalry

5.2 Value Chain Analysis

5.2.1 Device Manufacturers

5.2.2 Software developers

5.2.3 Reagent and accessory suppliers

5.2.4 Healthcare providers

5.2.5 Patients

6.1 Introduction

6.2 Circulating Tumor Cells (CTCs)

6.3 Circulating Tumour DNA (CtDNA)

6.4 Extracellular Vesicles (EVs)

6.5 Other biomarker (circulating RNA and proteins)

7.1 Introduction

7.2 Cancer

7.3 Reproductive health

7.4 Other therapeutic application

8.1 Introduction

8.2 Blood Sample

8.3 Urine sample

8.4 Other sample

9.1 Introduction

9.2 Hospitals and Laboratories

9.3 Academic and Research Centres

9.4 Other end users 56

10.1 Introduction

10.2 North America

10.2.1 US

10.2.2 CANADA

10.3 Europe

10.3.1 Germany

10.3.2 France

10.3.3 U.K.

10.3.4 Italy

10.3.5 Spain

10.3.6 Rest of Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Korea

10.4.6 Rest of Asia Pacific

10.5 Middle East and Africa

10.5.1 UAE

10.5.2 Saudi Arabia

10.5.3 Egypt

10.5.4 Rest of Middle East and Africa

11.1 Guardant Health, Inc

11.1.1 Company Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Overview

11.1.4 Key Development

11.1.5 SWOT Analysis

11.2 Trovagene, Inc

11.2.1 Company Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Overview

11.2.4 SWOT Analysis

11.3 RainDance Technologies, Inc.

11.3.1 Company Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Agena Bioscience Inc. Inc.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Admera Health

11.5.1 Company Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Overview

11.5.4 Key Development

11.5.5 SWOT Analysis

11.6 Biocept, Inc.

11.6.1 Company Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Overview

11.6.4 Key Development

11.7 Circulogene Theranostics

11.7.1 Company Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Overview

11.7.4 Key Development

11.8 Inivata Ltd

11.8.1 Company Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.9 SAGA Diagnostics AB

11.9.1 Company Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financial Overview

11.9.4 Key Development

11.10 Exosome Diagnostics

11.10.1 Company Overview

11.10.2 Product/Business Segment Overview

11.10.3 Financial Overview

11.10.4 Key Development

TABLE 1 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE, $ MILLION (2016-2022) 34
TABLE 2 CIRCULATING TUMOR CELLS (CTCS) MARKET, BY REGION, 2014-2022 ($ MILLION) 36
TABLE 3 CIRCULATING TUMOUR DNA (CTDNA) MARKET, BY REGION, 2014-2022 ($ MILLION) 38
TABLE 4 EXTRACELLULAR VESICLES (EVS) MARKET, BY REGION, 2014-2022 ($ MILLION) 39
TABLE 5 OTHER BIOMARKER TYPE MARKET, BY REGION, 2014-2022 ($ MILLION) 40
TABLE 6 GLOBAL LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 42
TABLE 7 CANCER THERAPEUTIC APPLICATION MARKET, BY REGION, 2014-2022 ($ MILLION) 43
TABLE 8 REPRODUCTIVE HEALTH THERAPEUTIC APPLICATION MARKET, BY REGION, 2014-2022 ($ ILLION) 44
TABLE 9 OTHER THERAPEUTIC APPLICATION MARKET, BY REGION, 2014-2022 ($ MILLION) 45
TABLE 10 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE, 2014-2022 ($ MILLION) 47
TABLE 11 BLOOD SAMPLE MARKET, BY REGION, 2014-2022 ($ MILLION) 49
TABLE 12 URINE SAMPLE MARKET, BY REGION, 2014-2022 ($ MILLION) 50
TABLE 13 OTHER SAMPLE MARKET, BY REGION, 2014-2022 ($ MILLION) 51
TABLE 14 GLOBAL LIQUID BIOPSY MARKET BY END USER, 2014-2022 ($ MILLION) 52
TABLE 15 HOSPITALS AND LABORATORIES END USERS MARKET, BY REGION, 2014-2022 ($ MILLION) 54
TABLE 16 ACADEMIC AND RESEARCH CENTERS END USERS MARKET, BY REGION, 2014-2022 ($ MILLION) 55
TABLE 17 OTHER END USERS MARKET, BY REGION, 2014-2022 ($ MILLION) 56
TABLE 18 GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2014-2022 ($ MILLION) 57
TABLE 19 NORTH AMERICALIQUID BIOPSY MARKET, BY COUNTRY, 2014-2022 ($ MILLION) 59
TABLE 20 NORTH AMERICA LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 60
TABLE 21 NORTH AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 61
TABLE 22 NORTH AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 62
TABLE 23 NORTH AMERICA LIQUID BIOPSY MARKET BY END USERS 63
TABLE 24 U.S. LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 64
TABLE 25 U.S. LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 65
TABLE 26 U.S. LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 66
TABLE 27 U.S. LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 67
TABLE 28 CANADA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 68
TABLE 29 CANADA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 69
TABLE 30 CANADA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 70
TABLE 31 CANADA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 71
TABLE 32 EUROPE LIQUID BIOPSY MARKET BY COUNTRY, 2014-2022 ($ MILLION) 72
TABLE 33 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 73
TABLE 34 EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 74
TABLE 35 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 75
TABLE 36 EUROPE LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 76
TABLE 37 GERMANY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 77
TABLE 38 GERMANY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 78
TABLE 39 GERMANY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 79
TABLE 40 GERMANY LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 80
TABLE 41 FRANCE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 81
TABLE 42 FRANCE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 82
TABLE 43 FRANCE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 83
TABLE 44 FRANCE LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 84
TABLE 45 U.K. LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 85
TABLE 46 U.K. LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 86
TABLE 47 U.K. LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 87
TABLE 48 U.K. LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 88
TABLE 49 ITALY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 89
TABLE 50 ITALY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 90
TABLE 51 ITALY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 91
TABLE 52 ITALY LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 92
TABLE 53 SPAIN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 93
TABLE 54 SPAIN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 94
TABLE 55 SPAIN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 95
TABLE 56 SPAIN LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 96
TABLE 57 REST OF EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 97
TABLE 58 REST OF EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 98
TABLE 59 REST OF EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 99
TABLE 60 REST OF EUROPE LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 100
TABLE 61 ASIA PACIFIC LIQUID BIOPSY MARKET BY COUNTRY, 2014-2022 ($ MILLION) 102
TABLE 62 ASIA PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 103
TABLE 63 ASIA PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 104
TABLE 64 ASIA PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 105
TABLE 65 ASIA PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 106
TABLE 66 JAPAN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 107
TABLE 67 JAPAN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 108
TABLE 68 JAPAN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 109
TABLE 69 JAPAN LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 110
TABLE 70 CHINA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 111
TABLE 71 CHINA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 112
TABLE 72 CHINA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 113
TABLE 73 CHINA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 114
TABLE 74 INDIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 115
TABLE 75 INDIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 116
TABLE 76 INDIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 117
TABLE 77 INDIA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 118
TABLE 78 AUSTRALIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 119
TABLE 79 AUSTRALIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 120
TABLE 80 AUSTRALIA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 122
TABLE 81 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 123
TABLE 82 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 124
TABLE 83 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 125
TABLE 84 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 126
TABLE 85 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 127
TABLE 86 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 128
TABLE 87 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 129
TABLE 88 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 130
TABLE 89 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY COUNTRY, 2014-2022 ($ MILLION) 132
TABLE 90 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 133
TABLE 91 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 134
TABLE 92 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 135
TABLE 93 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 136
TABLE 94 UAE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 137
TABLE 95 UAE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 138
TABLE 96 UAE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 139
TABLE 97 UAE LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 140
TABLE 98 SAUDI ARABIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 141
TABLE 99 SAUDI ARABIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 142
TABLE 100 SAUDI ARABIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 143
TABLE 101 SAUDI ARABIA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 144
TABLE 102 EGYPT LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 145
TABLE 103 EGYPT LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 146
TABLE 104 EGYPT LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 147
TABLE 105 EGYPT LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 148
TABLE 106 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 149
TABLE 107 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 150
TABLE 108 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 151
TABLE 109 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY END USERS, 2014-2022 ($ MILLION) 152
TABLE 110 GUARDANT HEALTH, INC: KEY DEVELOPMENT 155
TABLE 111 TROVAGENE, INC CORPORATION: KEY DEVELOPMENT 158
TABLE 112 RAINDANCE TECHNOLOGIES, INC. KEY DEVELOPMENT 160
TABLE 113 AGENA BIOSCIENCE INC.: KEY DEVELOPMENT 161
TABLE 114 ADMERA HEALTH: KEY DEVELOPMENT 163
TABLE 115 BIOCEPT, INC.: KEY DEVELOPMENT 165
TABLE 116 : CIRCULOGENE THERANOSTICS: KEY DEVELOPMENT 166
TABLE 117 INIVATA LTD: KEY DEVELOPMENT 167
TABLE 118 TABLE 8: SAGA DIAGNOSTICS AB: KEY DEVELOPMENT 168
TABLE 119 EXOSOME DIAGNOSTICSIS: KEY DEVELOPMENT 169

FIGURE 1 GLOBAL LIQUID BIOPSY: MARKET STRUCTURE 17
FIGURE 2 RESEARCH PROCESS OF MRFR 18
FIGURE 3 GLOBAL LIQUID BIOPSY: PORTER FIVE FORCES ANALYSIS 29
FIGURE 4 GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, MARKET SHARE 2016 (%) 35
FIGURE 5 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 $ MILLION 35
FIGURE 6 CIRCULATING TUMOR CELLS (CTCS) MARKET, BY REGION, 2016, $ MILLION 37
FIGURE 7 CIRCULATING TUMOR DNA (CTDNA) MARKET, BY REGION, 2016, $ MILLION 38
FIGURE 8 EXTRACELLULAR VESICLES (EVS) MARKET, BY REGION, 2016 $ MILLION 39
FIGURE 9 OTHER BIOMARKER TYPE MARKET, BY REGION, 2016, ($ MILLION) 40
FIGURE 10 GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATIONS, MARKET SHARE 2016 (%) 42
FIGURE 11 GLOBAL LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016, ($ MILLION) 43
FIGURE 12 CANCER THERAPEUTIC APPLICATION MARKET, BY REGION, 2016, ($ MILLION) 44
FIGURE 13 REPRODUCTIVE HEALTH THERAPEUTIC APPLICATION MARKET, BY REGION, 2016, ($ MILLION) 45
FIGURE 14 OTHER THERAPEUTIC APPLICATION MARKET, BY REGION, 2016, ($ MILLION) 46
FIGURE 15 GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE, MARKET SHARE 2016 (%) 48
FIGURE 16 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE, 2016, $ MILLION 48
FIGURE 17 BLOOD SAMPLE MARKET, BY REGION, 2014-2022 ($ MILLION) 49
FIGURE 18 URINE SAMPLE MARKET, BY REGION, 2016, $ MILLION 50
FIGURE 19 OTHER SAMPLE MARKET, BY REGION, 2016 ($ MILLION) 51
FIGURE 20 GLOBAL LIQUID BIOPSY MARKET, BY END USER, MARKET SHARE 2016 (%) 53
FIGURE 21 GLOBAL LIQUID BIOPSY MARKET BY END USER, 2016, $ MILLION 53
FIGURE 22 HOSPITALS AND LABORATORIES END USERS MARKET BY REGION, 2016, $ MILLION 54
FIGURE 23 ACADEMIC AND RESEARCH CENTERS END USERS MARKET, BY REGION, 2016, $ MILLION 55
FIGURE 24 OTHER END USERS MARKET, BY REGION, 2016, $ MILLION 56
FIGURE 25 GLOBAL LIQUID BIOPSY MARKET, BY REGION, MARKET SHARE 2016 (%) 58
FIGURE 26 GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2014-2022 ($ MILLION) 58
FIGURE 27 NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, MARKET SHARE 2016 (%) 59
FIGURE 28 NORTH AMERICA LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, 2016 ($ MILLION) 60
FIGURE 29 NORTH AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 61
FIGURE 30 NORTH AMERICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2016 ($ MILLION) 62
FIGURE 31 NORTH AMERICALIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 63
FIGURE 32 U.S. LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 64
FIGURE 33 U.S. LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 65
FIGURE 34 U.S. LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 66
FIGURE 35 U.S. LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 67
FIGURE 36 CANADA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 68
FIGURE 37 CANADA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 69
FIGURE 38 CANADA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 70
FIGURE 39 CANADA LIQUID BIOPSY MARKET BY END USERS, 2016, ($ MILLION) 71
FIGURE 40 EUROPE LIQUID BIOPSY MARKET BY COUNTRY, MARKET SHARE 2016 (%) 72
FIGURE 41 EUROPE LIQUID BIOPSY MARKET BY COUNTRY, 2016 ($ MILLION) 73
FIGURE 42 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 74
FIGURE 43 EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 75
FIGURE 44 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 76
FIGURE 45 EUROPE LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 77
FIGURE 46 GERMANY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 78
FIGURE 47 GERMANY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 79
FIGURE 48 GERMANY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 80
FIGURE 49 GERMANY LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 81
FIGURE 50 FRANCE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 82
FIGURE 51 FRANCE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 83
FIGURE 52 FRANCE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 84
FIGURE 53 FRANCE LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 85
FIGURE 54 U.K. LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 86
FIGURE 55 U.K. LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 87
FIGURE 56 U.K. LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 88
FIGURE 57 U.K. LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 89
FIGURE 58 ITALY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 90
FIGURE 59 ITALY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 91
FIGURE 60 ITALY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 92
FIGURE 61 ITALY LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 93
FIGURE 62 SPAIN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 94
FIGURE 63 SPAIN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 95
FIGURE 64 SPAIN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 96
FIGURE 65 SPAIN LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 97
FIGURE 66 REST OF EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 98
FIGURE 67 REST OF EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 99
FIGURE 68 REST OF EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 100
FIGURE 69 REST OF EUROPE LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 101
FIGURE 70 ASIA PACIFIC LIQUID BIOPSY MARKET BY COUNTRY, MARKET SHARE 2016 (%) 102
FIGURE 71 ASIA PACIFIC LIQUID BIOPSY MARKET BY COUNTRY, 2016 ($ MILLION) 103
FIGURE 72 ASIA PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 104
FIGURE 73 ASIA PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 105
FIGURE 74 ASIA PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 106
FIGURE 75 ASIA PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 107
FIGURE 76 JAPAN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2014-2022 ($ MILLION) 108
FIGURE 77 JAPAN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 109
FIGURE 78 JAPAN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 110
FIGURE 79 JAPAN LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 111
FIGURE 80 CHINA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 112
FIGURE 81 CHINA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 113
FIGURE 82 CHINA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 114
FIGURE 83 CHINA LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 115
FIGURE 84 INDIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 116
FIGURE 85 INDIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 117
FIGURE 86 INDIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 118
FIGURE 87 INDIA LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 119
FIGURE 88 AUSTRALIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 120
FIGURE 89 AUSTRALIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 121
FIGURE 90 AUSTRALIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2014-2022 ($ MILLION) 121
FIGURE 91 AUSTRALIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 122
FIGURE 92 AUSTRALIA LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 123
FIGURE 93 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 124
FIGURE 94 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 125
FIGURE 95 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 126
FIGURE 96 REPUBLIC OF KOREA LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 127
FIGURE 97 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 128
FIGURE 98 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 129
FIGURE 99 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 130
FIGURE 100 REST OF ASIA PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 131
FIGURE 101 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, MARKET SHARE BY COUNTRY, 2016 (%) 132
FIGURE 102 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY COUNTRY, 2016 ($ MILLION) 133
FIGURE 103 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 134
FIGURE 104 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 135
FIGURE 105 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 136
FIGURE 106 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 137
FIGURE 107 UAE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 138
FIGURE 108 UAE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 139
FIGURE 109 UAE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 140
FIGURE 110 UAE LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 141
FIGURE 111 SAUDI ARABIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 142
FIGURE 112 SAUDI ARABIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 143
FIGURE 113 SAUDI ARABIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 144
FIGURE 114 SAUDI ARABIA LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 145
FIGURE 115 EGYPT LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 146
FIGURE 116 EGYPT LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 147
FIGURE 117 EGYPT LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 148
FIGURE 118 EGYPT LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 149
FIGURE 119 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 ($ MILLION) 150
FIGURE 120 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2016 ($ MILLION) 151
FIGURE 121 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2016 ($ MILLION) 152
FIGURE 122 REST OF MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY END USERS, 2016 ($ MILLION) 153
FIGURE 123 GUARDANT HEALTH, INC: SWOT ANALYSIS 156
FIGURE 124 TROVAGENE, INC; RECENT FINANCIALS 157
FIGURE 125 TROVAGENE, INC CORPORATION: SWOT ANALYSIS 158
FIGURE 126 RAINDANCE: RECENT FINANCIAL 159
FIGURE 127 RAINDANCE TECHNOLOGIES: SWOT ANALYSIS 160
FIGURE 128 AGENA BIOSCIENCE INC.: SWOT ANALYSIS 162
FIGURE 129 ADMERA HEALTH: SWOT ANALYSIS 164